Subjects (n = 32 for both studies) were to receive 1 week's treatment with esomeprazole 40mg once daily (studies A and B), naproxen 250mg twice daily (study A), rofecoxib 12.5mg once daily (study ...

In 65.1% and 69.6% of patients in the lornoxicam and rofecoxib groups, respectively, the underlying disease existed for at least 181 days ( Table I). Before the beginning of the study, patients ...

Triggered by concerns over an increased risk of cardiovascular side effects, Merck announced on 30 September the withdrawal of rofecoxib (Vioxx), its leading drug for the management of rheumatoid ...

However, the withdrawal of the selective cyclo-oxygenase 2 (COX2) inhibitor rofecoxib in 2004, based on evidence of an increased risk of adverse cardiovascular events in users of this drug ...

In 2004, the withdrawal of Vioxx (rofecoxib), a nonsteroidal anti-inflammatory drug manufactured by Merck and widely prescribed for managing arthritis pain, revealed a critical vulnerability in ...